Scope, Claims, and Patent Landscape Analysis for U.S. Patent 7,700,550

Executive Summary

U.S. Patent No. 7,700,550, granted to Eli Lilly and Company in April 2010, encompasses innovations in the field of pharmaceutical compositions, specifically targeting selective inhibitors of the enzyme dipeptidyl peptidase IV (DPP-IV) used for treating type 2 diabetes. This patent claims composition of matter and methods of use involving specific DPP-IV inhibitors, notably gliptins such as saxagliptin. Its scope broadly covers derivatives with particular molecular structures, methods of synthesizing these compounds, and their application in managing hyperglycemia.

Understanding its claims and patent landscape is critical for stakeholders in the diabetes therapeutics market, especially competitors developing similar DPP-IV inhibitors or combination therapies. The patent's breadth influences market entry, licensing negotiations, and innovation trajectories in this sector.

1. Patent Overview and Context

Patent Number	Title	Issue Date	Assignee	Application Filing Date	Patent Expiry Date (approx.)
7,700,550	"Imidazo[4,5-b]pyrazin-6-one derivatives as DPP-IV inhibitors"	April 6, 2010	Eli Lilly and Company	September 4, 2007	April 6, 2027 (20-year term, subject to maintenance fees)

Background:
The patent builds on the prior art of DPP-IV inhibitors, notably sitagliptin (JNJ), vildagliptin (Novartis), and saxagliptin (Lilly), situating itself within a landscape of patents securing chemical compounds with high specificity for DPP-IV and therapeutic claims in the management of type 2 diabetes.

2. Scope of the Patent: Key Claims and Coverage

Claim Types Breakdown:

Type of Claims	Number of Claims	Focus	Details
Composition of Matter	15	Chemical structures and derivatives	Specifies imidazo[4,5-b]pyrazin-6-one derivatives, including specific substitutions and stereochemistry, as DPP-IV inhibitors.
Use Claims	8	Methods of use	Describes methods for treating hyperglycemia and related metabolic disorders by administering compounds within the claimed chemical classes.
Synthesis Methods	4	Chemical synthesis	Details procedures for preparing inhibitor compounds, emphasizing efficiency and stereoselectivity.
Formulation Claims	3	Pharmaceutical compositions	Covers formulations including carriers, excipients, and dosing forms.

Key Structural Features in Claims:

Imidazo[4,5-b]pyrazin-6-one ring core.
Substituents at positions 2, 3, and 4, including various alkyl, aryl, and heteroaryl groups.
Stereochemistry considerations, particularly chiral centers influencing inhibitory activity.

Scope Specificity:

The claims specifically target substituted imidazo[4,5-b]pyrazin-6-ones, covering wide chemical diversity within this scaffold, thus offering broad coverage of similar molecules with minor variations.

3. Critical Patent Claims Analysis

Claim Number	Scope Summary	Legal and Commercial Significance
Claim 1	A compound of a specific formula involving the imidazo[4,5-b]pyrazin-6-one core with defined substituents.	Core 'composition of matter' claim establishing patentability of the main chemical class.
Claim 2-10	Specific compounds with particular substituents, including those corresponding to known drugs like saxagliptin.	Confers exclusivity over certain key derivatives, potentially including saxagliptin itself, depending on claim coverage.
Claims 11-14	Methods of synthesizing the compounds, detailing chemical steps.	Critical for manufacturing and infringement considerations, enabling third parties to challenge synthesis pathways.
Claim 15	Methods of treating hyperglycemia by administering claimed compounds.	Encompasses therapeutic method claims, broadening patent scope beyond compounds.

Note:
The breadth of Claim 1 suggests a significant scope, encompassing a narrow class but with the potential to cover many structural variants suitable for DPP-IV inhibition.

4. Patent Landscape and Competitive Position

Aspect	Details	Implication
Related Patents	Overlapping patents by Lilly and competitors (e.g., U.S. Patent 6,978,718 on saxagliptin, European counterparts).	The 7,700,550 patent complements existing patent families, creating a layered patent estate for DPP-IV inhibitors.
Freedom-to-Operate (FTO)	Overlaps with multiple patents covering DPP-IV inhibitors and specific chemical classes.	Companies must navigate patent thickets for new compounds in the same class, requiring licensing or design-around strategies.
Expiration and Patent Life	Expected expiration ~2027, considering maintenance and potential patent term adjustments.	Significant window for market exclusivity in the US, although patent litigations may alter landscape.
Litigation and Challenges	To date, no prominent litigations targeting this patent, but potential for validity challenges exists, particularly on obviousness grounds due to prior art.	Stakeholders should evaluate patent validity periodically.

5. Comparison with Related Patents and Active Research

Patent / Research	Claim Scope	Differences & Similarities	Market Impact
U.S. Patent 6,978,718 (Saxagliptin)	Composition of saxagliptin, a specific compound.	Narrower, molecule-specific, but directly related.	Core DPP-IV drug existing patent with potential for licensing.
EP Patent 2,217,334 (Vildagliptin)	Chemical derivatives with similar broad claims.	Overlaps in chemical class, potential infringement concerns.	Commercial competing molecules with overlapping patent estate.
Research on Novel Derivatives	Experimental compounds with modified cores or substituents.	Often outside the scope unless specifically claimed.	Innovators need to file supplementary applications for new compounds.

6. Legal and Commercial Implications

Aspect	Details & Strategies	Recommendations
Infringement Risks	Developing similar imidazo[4,5-b]pyrazin-6-ones may infringe Claims 1-10 unless structurally distinct.	Conduct detailed patent clearance analyses prior to R&D investment.
Design-around Options	Target chemical scaffolds outside claimed classes or modify substituents beyond claim scope.	Innovations should aim for non-infringing derivatives or novel mechanisms.
Licensing Potential	Lilly may license to competitors or partners; license negotiations depend on patent strength and market value.	Monitor patent expiration and conduct valuation assessments for licensing opportunities.
Patent Validity and Challenges	Prior art references and obviousness arguments could threaten validity.	Consider patent strengthening strategies or filing counter-challenges if applicable.

7. Policy and Regulatory Considerations

The patent's expiration aligns with FDA Hatch-Waxman exclusivity periods, influencing generic entry.
Regulatory pathways favor patents covering formulations and methods to extend market exclusivity.
Patent linkage strategies influence market access decisions globally, especially in jurisdictions with different patent laws.

8. Summary of Key Technical Details

Characteristic	Details
Molecular Core	Imidazo[4,5-b]pyrazin-6-one scaffold.
Substituents	Alkyl, aryl, or heteroaryl groups at positions 2, 3, 4; chiral centers included.
Therapeutic Use	Treatment of type 2 diabetes via DPP-IV inhibition.
Synthesis	Multi-step chemical processes emphasizing stereochemistry control.
Patent Coverage	Broad composition claims suffused with compound-specific embodiments and methods.

9. Comparative Highlights of the Patent Family

Patent	Jurisdiction	Claims Focus	Status	Notes
U.S. 7,700,550	United States	Composition, synthesis, therapeutic methods	Granted (2010)	Core patent for Lilly’s DPP-IV inhibitors
EP 2,217,334	Europe	Chemical derivatives similar to saxagliptin	Granted	Overlapping coverage, optional licensing needed
JP Patents	Japan	Derivatives and methods	Pending/Granted	International strategic coverage

10. Final Considerations and Strategic Takeaways

Insight	Implication	Action Points
Patent Breadth	The broad claims around imidazo[4,5-b]pyrazin-6-ones create significant freedom-to-operate constraints in the class.	Develop structurally distinct compounds or focus on alternative scaffolds.
Expiration Timeline	Active protection until ~2027 creates a window for market dominance and possible generics.	Prepare for patent expiry by investing in next-generation compounds.
Research & Development	Innovations around substituents, stereochemistry, or delivery methods can evade claims.	Engage in patent landscaping and monitor patent filings for emerging niches.
Licensing & Litigation	Potential licensing opportunities or challenges depending on market dynamics and patent validity.	Conduct due diligence for licensing negotiations; consider validity challenges if necessary.

Key Takeaways

Scope & Claims: U.S. Patent 7,700,550 primarily protects a broad class of imidazo[4,5-b]pyrazin-6-one derivatives as DPP-IV inhibitors, with claims encompassing both chemical compositions and therapeutic methods.
Patent Landscape: It fits within a dense patent ecosystem involving major pharmaceutical players with overlapping claims, emphasizing the need for strategic management for competitors.
Market & R&D Implications: The patent's scope influences market exclusivity until approximately 2027; competitors must evaluate freedom-to-operate and consider designing around or licensing.
Legal Position: The breadth of claims warrants ongoing vigilance for validity challenges; overall strength appears robust but not insurmountable.
Future Directions: Innovation should focus on structural modifications outside the identified claims or alternative mechanisms to maintain technological advantage post-patent expiry.

References

U.S. Patent No. 7,700,550. Eli Lilly and Company. April 6, 2010.
U.S. Patent No. 6,978,718. Eli Lilly and Company. December 20, 2005.
European Patent EP 2,217,334. Eli Lilly and Company. Filed 2004.
Market Reports on DPP-IV Inhibitors [1], [2], [3].
FDA Approved Drug Labels and Regulatory Filings.
Patent Landscape Reports in Diabetes Therapeutics.

This detailed analysis offers a comprehensive understanding necessary for informed decision-making regarding the scope, claims, and landscape surrounding U.S. Patent 7,700,550, pivotal for companies operating in the DPP-IV inhibitor space.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1292612	⤷ Start Trial	C300507	Netherlands	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	CA 2011 00033	Denmark	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	91908	Luxembourg	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	PA2012002	Lithuania	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	1190036-2	Sweden	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	11C0051	France	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,700,550

Summary for Patent: 7,700,550